167316-27-0

Basic information

• Product Name: (1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine
• Synonyms: (S,S)-N-(P-TOLUENESULFONYL)-1,2-DIPHENYLETHYLENEDIAMINE;(S,S)-TSDPEN;(1S, 2S)-(+)-N-(4-TOLUENE SULFONYL)1,2-DIPHENYL-1,2-ETHANE DIAMINE;(1S,2S)-N-(4-TOLUENESULFONYL)-1,2-DIPHENYLETHYLENE-1,2-DIAMINE;(1S,2S)-(+)-N-(4-TOLUENESULFONYL)-1,2-DIPHENYLETHYLENEDIAMINE;(1S,2S)-(+)-N-(4-TOLUENESULPHONYL)-1,2-DIPHENYLETHYLENEDIAMINE;(1S,2S)-TSDPEN;(1S,2S)-N-(P-TOLUENESULFONYL)-1,2-DIPHENYL-1,2-ETHANEDIAMINE
• CAS NO: 167316-27-0
• Molecular Formula: C₂₁H₂₂N₂O₂S
• Molecular Weight: 366.48
• Product Categories: API intermediates;Asymmetric Synthesis;Synthetic Organic Chemistry;Asymmetric Synthesis;Chiral Catalysts, Ligands, and Reagents;HydrogenationChiral Building Blocks;Organic Building Blocks;Polyamines;organic amine;Chiral Nitrogen;DPEN Series
• Mol File: 167316-27-0.mol

Chemical Properties

• Melting Point: 128-131 °C(lit.)
• Boiling Point: 537.3 °C at 760 mmHg
• Flash Point: 278.8 °C
• Appearance: white/crystal
• Density: 1.1440 (rough estimate)
• Vapor Pressure: 1.28E-11mmHg at 25°C
• Refractive Index: 30 ° (C=1, CHCl3)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• Solubility: Solubility in hot Acetonitrile (almost transparency).
• PKA: 10.76±0.50(Predicted)
• CAS DataBase Reference: (1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine(CAS DataBase Reference)
• NIST Chemistry Reference: (1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine(167316-27-0)
• EPA Substance Registry System: (1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine(167316-27-0)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 167316-27-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine is used as a catalyst for the synthesis of keramamine C, a carboline alkaloid isolated from the Okinawan sponge Amphimedon sp. (1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine has potential applications in the development of new pharmaceuticals due to its unique chemical structure and properties.
Used in Medical Treatment:
In the medical field, (1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine is used as a catalyst in the synthesis of Tolvaptan (T536650), a selective oral vasopressin V2-receptor agonist. Tolvaptan is utilized for the treatment of hyponatremia, a condition characterized by low sodium levels in the blood, and the use of this catalyst aids in the efficient production of the drug.
Overall, (1S,2S)-(+)-N-(4-Toluenesulfonyl)-1,2-diphenylethylenediamine is a valuable compound with applications in the pharmaceutical and medical industries, primarily as a catalyst in the synthesis of specific compounds. Its enhanced catalytic efficiency and adherence to greener chemistry principles make it a preferred choice for various chemical processes.

InChI:InChI=1/C21H22N2O2S/c1-16-12-14-19(15-13-16)26(24,25)23-21(18-10-6-3-7-11-18)20(22)17-8-4-2-5-9-17/h2-15,20-21,23H,22H2,1H3/p+1/t20-,21-/m0/s1

Upstream product

• 29841-69-8 (S,S)-1,2-diphenyl-1,2-diaminoethane 
• 98-59-9 p-toluenesulfonyl chloride 
• 530-36-9 (1S,2S)-2-amino-1,2-diphenylethanol 

Downstream Products

• 191592-36-6 (-)-(S)-5-[3-[4-(4-fluorophenyl)piperazin-1-yl]propyl]-8-hydroxy-1-methyl-1,4,5,6,7,8-hexahydropyrrolo[3,2-c]azepin-4-one 
• 1043450-10-7 (1S,2S)-N-(1,2-diphenyl-2-(piperidin-1-yl)ethyl)-4-methyl-benzenesulfonamide 
• 1234856-69-9 C₅₆H₅₁N₅O₆S₂ 
• 1295509-73-7 C₄₂H₄₅N₅O₃S₂ 
• 1420887-45-1 C₃₂H₃₉N₃O₅S 
• 1420887-32-6 (2S)-1-formyl-N-[(1S,2S)-2-([(4-methylphenyl)sulfonyl]amino)-1,2-diphenylethyl]piperidine-2-carboxamide 

Relevant articles and documents

Chiral nitrogen-metal complexes for the asymmetric reduction of ketones

Chiral cobalt-diamine complexes have been prepared and tested in catalytic reduction of β-ketoesters and ketones with molecular hydrogen or hydride transfer reduction (HTR). Modest to high conversions, but low e.e.s were obtained in the first case, wherea

Enantioselective Total Syntheses of (+)-Arborescidine A, (-)-Arborescidine B, and (-)-Arborescidine C

Described are the first enantioselective total syntheses of (+)-arborescidine A ((+)-1), (-)-arborescidine B ((-)-2), and (-)-arborescidine C ((-)-3), via routes that proceeded in five steps and 50% overall yield, eight steps and 61% overall yield, and ni

2-[(2R, 6S)-6-[(2S)-2-hydroxy-2-phenethyl]-1-pipecoline]-1-hypnone synthesis method

The invention discloses a 2-[(2R, 6S)-6-[(2S)-2-hydroxy-2-phenethyl]-1-pipecoline]-1-hypnone synthesis method, and belongs to the field of organic synthesis. (1S, 2S)-1, 2-diphenyl diaminoethane serving as a raw material is subjected to acylation, substitution and the like to prepare chiral amine catalysts. A main route totally includes two steps: synthesizing glutaraldehyde, benzoyl acetic acid and methylamine hydrochloride to form cis-lobelanine; performing asymmetric selective reduction synthesis of 2-[(2R, 6S)-6-[(2S)-2-hydroxy-2-phenethyl]-1-pipecoline]-1-hypnone under mild reaction conditions and under the action of the catalysts. The raw material in the whole process route is cheap and easy to obtain, the catalysts can be recycled and can continue to be used, and the synthesis method is low in cost, simple in process, mild in reaction condition, convenient in operation and high in total yield.

Divergent de novo synthesis of all eight stereoisomers of 2,3,6-trideoxyhexopyranosides and their oligomers

All eight possible stereoisomers of 2,3,6-trideoxyhexopyranosides are prepared systematically from furan derivatives by a sequence of Achmatowicz rearrangement, Pd-catalysed glycosidation, and chiral catalyst-controlled tandem reductions. This sequence provides access to all possible stereoisomers of naturally occurring rhodinopyranosides, amicetopyranosides, disaccharide narbosine B, and other unnatural oligomeric 2,3,6-trideoxyhexopyranosides. It comprises a unique and systematic strategy for the de novo synthesis of deoxysugars.

L-Pipecolinic acid derived Lewis base organocatalyst for asymmetric reduction of N-aryl imines by trichlorosilane: Effects of the side amide group on catalytic performances

A series of N-formamides derived from pipecolinic acid have been synthesized and tested as Lewis base catalysts for the enantioselective reduction of N-aryl imines by trichlorosilane. Through the investigation of the structure-efficacy relationship between the side amide group and catalytic performance, several highly effective catalysts were discovered. In particular, arylamido-type catalyst 5i and non-arylamido-type catalyst 6c exhibited high reactivity and enantioselectivity, furnishing the reduction of a wide variety of N-aryl imines with high isolated yields (up to 98%) and ee values (up to 96%) under mild conditions. Moreover, these two catalysts complement each other in terms of their tolerances to nonaromatic ketimines and non-methyl ketimines. The Royal Society of Chemistry 2013.

Catalytic asymmetric Michael addition with curcumin derivative

Catalytic asymmetric Michael additions with curcumin derivatives were achieved by a new series of tertiary amine-thiourea organocatalysts to afford the Michael adducts in high yields and excellent enantioselectivities.

COMPOSITIONS AND METHODS FOR CYCLOFRUCTANS AS SEPARATION AGENTS

The present invention relates to derivatized cyclofructan compounds, compositions comprising derivatized cyclofructan compounds, and methods of using compositions comprising derivatized cyclofructan compounds for chromatographic separations of chemical species, including enantiomers. Said compositions may comprise a solid support and/or polymers comprising derivatized cyclofructan compounds.

COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION

The invention relates to novel resolvin compounds and pharmaceutical preparations thereof. The invention further relates to methods of treatment using the novel resolvin compounds of the invention.

Biomimetic iron-catalyzed asymmetric epoxidation of aromatic alkenes by using hydrogen peroxide

A novel and general biomimetic non-heme Fe-catalyzed asymmetric epoxidation of aromatic alkenes by using hydrogen peroxide is reported herein. The catalyst consists of ferric chloride hexahydrate (FeCl3·OH 2O), pyridine-2,6-dicarboxylic acid (H2-(pydic)), and readily accessible chiral N-arenesulfonyl-N′-benzyl-substituted ethylenediamine ligands. The asymmetric epoxidation of styrenes with this system gave high conversions but poor enantiomeric excesses (ee), whereas larger alkenes gave high conversions and ee values. For the epoxidation of trans-stilbene (1a), the ligands (S,S)-N-(4-toluenesulfonyl)-1,2- diphenylethylenediamine ((S,S)-4a) and its N′-benzylated derivative ((S,S)-5a) gave opposite enantiomers of trans-stilbene oxide, that is, (S,S)-2a and (R,R)-2a, respectively. The enantioselectivity of alkene epoxidation is controlled by steric and electronic factors, although steric effects are more dominant. Preliminary mechanistic studies suggest the in situ formation of several chiral Fe-complexes, such as [FeCl(L*)2-(pydic)] ·HCl (L* = (S,S)-4a or (S,S)-5a in the catalyst mixture), which were identified by ESIMS. A UV/Vis study of the catalyst mixture, which consisted of FeCl3·6H2O, H2(pydic), and (S,S)-4a, suggested the formation of a new species with an absorbance peak at λ = 465 nm upon treatment with hydrogen peroxide. With the aid of two independent spin traps, we could confirm by EPR spectroscopy that the reaction proceeds via radical intermediates. Kinetic studies with deuterated styrenes showed inverse secondary kinetic isotope effects, with values of k H/kD = 0.93 for the β carbon and kH/k D=0.97 for the a carbon, which suggested an unsymmetrical transition state with stepwise O transfer. Competitive epoxidation of para-substituted styrenes revealed a linear dual-parameter Hammett plot with a slope of 1.00. Under standard conditions, epoxidation of la in the presence of ten equivalents of H218O resulted in an absence of the isotopic label in (S,S)-2a. A positive non-linear effect was observed during the epoxidation of la in the presence of (S,S)-5a and (R,R)-5a.

Preparation of mono-N-sulphonylated diamines

The present invention relates to a process for preparing mono-N-sulphonylated diamines by reacting diamines with sulphonyl halides in the presence of water, base and organic solvents.